BR112021024592A2 - Sequência líder - Google Patents

Sequência líder

Info

Publication number
BR112021024592A2
BR112021024592A2 BR112021024592A BR112021024592A BR112021024592A2 BR 112021024592 A2 BR112021024592 A2 BR 112021024592A2 BR 112021024592 A BR112021024592 A BR 112021024592A BR 112021024592 A BR112021024592 A BR 112021024592A BR 112021024592 A2 BR112021024592 A2 BR 112021024592A2
Authority
BR
Brazil
Prior art keywords
leader sequence
pvc
payload
effector
needle complex
Prior art date
Application number
BR112021024592A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexia Hapeshi
Joseph Healey
R Waterfield Nicholas
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of BR112021024592A2 publication Critical patent/BR112021024592A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BR112021024592A 2019-06-07 2020-06-05 Sequência líder BR112021024592A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
BR112021024592A2 true BR112021024592A2 (pt) 2022-01-18

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024592A BR112021024592A2 (pt) 2019-06-07 2020-06-05 Sequência líder

Country Status (12)

Country Link
US (1) US20230076614A1 (https=)
EP (1) EP3980545A1 (https=)
JP (2) JP7748288B2 (https=)
KR (1) KR20220133757A (https=)
CN (1) CN114008205A (https=)
AU (1) AU2020288380A1 (https=)
BR (1) BR112021024592A2 (https=)
CA (1) CA3142462A1 (https=)
GB (1) GB201908155D0 (https=)
MX (1) MX2021015121A (https=)
SG (1) SG11202113297RA (https=)
WO (1) WO2020245611A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158486A2 (en) * 2022-02-15 2023-08-24 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
WO2024003387A1 (en) 2022-06-30 2024-01-04 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2964240B1 (en) * 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
WO2017066479A1 (en) * 2015-10-14 2017-04-20 Bayer Cropscience Lp Axmi554 delta-endotoxin gene and methods for its use

Also Published As

Publication number Publication date
US20230076614A1 (en) 2023-03-09
JP2025114573A (ja) 2025-08-05
JP2022535283A (ja) 2022-08-05
GB201908155D0 (en) 2019-07-24
AU2020288380A1 (en) 2022-01-06
CN114008205A (zh) 2022-02-01
EP3980545A1 (en) 2022-04-13
MX2021015121A (es) 2022-03-17
KR20220133757A (ko) 2022-10-05
JP7748288B2 (ja) 2025-10-02
WO2020245611A1 (en) 2020-12-10
SG11202113297RA (en) 2021-12-30
CA3142462A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
BR112021024592A2 (pt) Sequência líder
BR112021022879A2 (pt) Sistemas e métodos para avaliação de fração tumoral
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
MX2020004578A (es) Composiciones de casz y metodos de uso.
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
CR20200392A (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112017003194A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra.
BR112017025564B8 (pt) Anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
BR112017012944A2 (pt) ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza?
BR112018073674A2 (pt) polipeptídeo glicosilado, proteína glicosilada, uso de um polipeptídeo glicosilado, composição, polinucleotídeo isolado, vetor, e célula hospedeira
MX2016014813A (es) Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
BR112018014018A2 (pt) métodos para detecção de um analito-alvo, para determinação de concentração de ácido picolínico e para detecção de concentração de um composto químico-alvo.
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112017026523A2 (pt) vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
BR112014024751A2 (pt) antígenos de clostridium difficile
EP4488372A3 (en) Method for enhancing sensitivity of endotoxin measuring agent

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NANOSYRINX LIMITED (GB)